In-Vivo CAR Therapies: Global Clinical Trial Landscape (2025)
Novotech’s latest white paper, In-Vivo CAR Therapies – Global Research and Development Landscape (2025), explores how this new class of immunotherapies could make cell therapy faster, more scalable, and more accessible.
While traditional Chimeric Antigen Receptor T-cell (CAR-T) therapies remain limited by manufacturing, cost, and logistics, in-vivo CAR-T platforms aim to engineer T cells directly inside the body, eliminating the need for ex-vivo production and opening the door to off-the-shelf delivery.
The report includes:
🔹 A global pipeline overview of in-vivo CAR-T assets and trials
🔹 Key innovations in viral vectors and lipid nanoparticle delivery
🔹 Emerging opportunities in solid tumors, autoimmune disease, and fibrosis
🔹 Regulatory and commercial considerations for biotech sponsors
If you’re in oncology, autoimmunity, or advanced therapeutics, this is essential reading.